Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results

Novo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.

This article was originally published here.